Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation

Medical Hypotheses

Volumn 92, Issue , 2016, Pages 67-73

  Demidowich, Andrew P ^a   Davis, Angela I ^a   Dedhia, Nicket ^a   Yanovski, Jack A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CRYOPYRIN; DOUBLE STRANDED DNA; FLAGELLIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTIGOUT AGENT; NLRP3 PROTEIN, HUMAN;

ADIPOCYTE; ARTICLE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC DISORDER; MICROTUBULE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; ADIPOSE TISSUE; ANIMAL; COMPLICATION; INNATE IMMUNITY; MACROPHAGE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

ADIPOSE TISSUE; ANIMALS; COLCHICINE; DIABETES MELLITUS, TYPE 2; GOUT SUPPRESSANTS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; METABOLIC DISEASES; MICE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OBESITY; RISK FACTORS;

EID: 84964556206     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.04.039     Document Type: Article

References (101)

1. Murphy N.F., MacIntyre K., Stewart S., Hart C.L., Hole D., McMurray J.J. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006, 27:96-106.
2. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. Jama-J Am Med Assoc 2006, 295:1549-1555.
3. Kuczmarski R.J., Flegal K.M., Campbell S.M., Johnson C.L. Increasing prevalence of overweight among US adults. The national health and nutrition examination surveys, 1960-1991. JAMA J Am Med Assoc 1994, 272:205-211.
4. Lumeng C.N., Deyoung S.M., Saltiel A.R. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007, 292:E166-E174.
5. Gao Z., Hwang D., Bataille F., et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002, 277:48115-48121.
6. Ramadan J.W., Steiner S.R., O'Neill C.M., Nunemaker C.S. The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes. Cell Calcium 2011, 50:481-490.
7. Dula S.B., Jecmenica M., Wu R., et al. Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium 2010, 48:133-142.
8. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
9. Clement K., Viguerie N., Poitou C., et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. Faseb J 2004, 18:1657-1669.
10. Wing R.R., Bolin P., Brancati F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154.
11. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 2009, 374:1677-1686.
12. Magro D.O., Geloneze B., Delfini R., Pareja B.C., Callejas F., Pareja J.C. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg 2008, 18:648-651.
13. Steffen R., Potoczna N., Bieri N., Horber F.F. Successful multi-intervention treatment of severe obesity: a 7-year prospective study with 96% follow-up. Obes Surg 2009, 19:3-12.
14. Yanovski S.Z., Yanovski J.A. Long-term drug treatment for obesity: a systematic and clinical review. JAMA J Am Med Assoc 2014, 311:74-86.
15. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26.
16. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
17. Liu Z.G., Hsu H., Goeddel D.V., Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996, 87:565-576.
18. Hirosumi J., Tuncman G., Chang L., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
19. Arkan M.C., Hevener A.L., Greten F.R., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-198.
20. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
21. Vandanmagsar B., Youm Y.H., Ravussin A., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011, 17:179-188.
22. Rui L., Yuan M., Frantz D., Shoelson S., White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002, 277:42394-42398.
23. Osborn O., Brownell S.E., Sanchez-Alavez M., Salomon D., Gram H., Bartfai T. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 2008, 44:141-148.
24. Westermark P., Andersson A., Westermark G.T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011, 91:795-826.
25. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
26. Donath M.Y., Ehses J.A., Maedler K., et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005, 54(Suppl 2):S108-S113.
27. Stienstra R., Joosten L.A., Koenen T., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010, 12:593-605.
28. McGillicuddy F.C., Harford K.A., Reynolds C.M., et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011, 60:1688-1698.
29. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
30. Kanda H., Tateya S., Tamori Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
31. Finucane O.M., Reynolds C.M., McGillicuddy F.C., et al. Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis. PLoS ONE 2014, 9:e113369.
32. Samad F., Yamamoto K., Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996, 97:37-46.
33. Festa A., D'Agostino R., Williams K., et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001, 25:1407-1415.
34. Pannacciulli N., Cantatore F.P., Minenna A., Bellacicco M., Giorgino R., De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001, 25:1416-1420.
35. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005, 69:29-35.
36. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA: J Am Med Assoc 1999, 282:2131-2135.
37. Bahceci M., Gokalp D., Bahceci S., Tuzcu A., Atmaca S., Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?. J Endocrinol Invest 2007, 30:210-214.
38. Reinehr T., Stoffel-Wagner B., Roth C.L., Andler W. High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. Metabolism 2005, 54:1155-1161.
39. Roth C.L., Kratz M., Ralston M.M., Reinehr T. Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism 2011, 60:445-452.
40. Giordano P., Del Vecchio G.C., Cecinati V., et al. Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. Eur J Pediatr 2011, 170:845-850.
41. Fisher G., Hyatt T.C., Hunter G.R., Oster R.A., Desmond R.A., Gower B.A. Markers of inflammation and fat distribution following weight loss in African-American and white women. Obesity (Silver Spring) 2012, 20:715-720.
42. Illan-Gomez F., Gonzalvez-Ortega M., Orea-Soler I., et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 2012, 22:950-955.
43. Lasselin J., Magne E., Beau C., et al. Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgery-induced weight loss. J Clin Endocrinol Metab 2014, 99:E53-E61.
44. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
45. Johnson A.R., Milner J.J., Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev 2012, 249:218-238.
46. Puri V., Ranjit S., Konda S., et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci USA 2008, 105:7833-7838.
47. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
48. Clement K., Viguerie N., Poitou C., et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004, 18:1657-1669.
49. Lumeng C.N., Deyoung S.M., Bodzin J.L., Saltiel A.R. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23.
50. Owyang A.M., Maedler K., Gross L., et al. XOMA 052, an anti-IL-1β monoclonal antibody, improves glucose control and β-cell function in the diet-induced obesity mouse model. Endocrinology 2010, 151:2515-2527.
51. Sauter N.S., Schulthess F.T., Galasso R., Castellani L.W., Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008, 149:2208-2218.
52. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996, 45:881-885.
53. Klover P.J., Clementi A.H., Mooney R.A. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005, 146:3417-3427.
54. Weisberg S.P., Hunter D., Huber R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115-124.
55. Kim J.E., Lee M.H., Nam D.H., et al. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PLoS ONE 2013, 8:e62068.
56. Stanley T.L., Zanni M.V., Johnsen S., et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011, 96:E146-E150.
57. Pradhan A.D., Cook N.R., Manson J.E., Ridker P.M., Buring J.E. A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. Diabetes Care 2009, 32:3-8.
58. Ridker P.M., Howard C.P., Walter V., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748.
59. Rissanen A., Howard C.P., Botha J., Thuren T. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diab Obes Metab 2012, 14:1088-1096.
60. Cavelti-Weder C., Babians-Brunner A., Keller C., et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012, 35:1654-1662.
61. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
62. van Asseldonk E.J., Stienstra R., Koenen T.B., Joosten L.A., Netea M.G., Tack C.J. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011, 96:2119-2126.
63. Abramson S., Korchak H., Ludewig R., et al. Modes of action of aspirin-like drugs. Proc Natl Acad Sci USA 1985, 82:7227-7231.
64. Pillinger M.H., Capodici C., Rosenthal P., et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 1998, 95:14540-14545.
65. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
66. Goldfine A.B., Fonseca V., Jablonski K.A., Pyle L., Staten M.A., Shoelson S.E. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010, 152:346-357.
67. Guarda G., Zenger M., Yazdi A.S., et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011, 186:2529-2534.
68. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
69. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
70. Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010, 11:897-904.
71. Jiang Y., Wang M., Huang K., et al. Oxidized low-density lipoprotein induces secretion of interleukin-1beta by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun 2012, 425:121-126.
72. Legrand-Poels S., Esser N., L'Homme L., Scheen A., Paquot N., Piette J. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Biochem Pharmacol 2014, 92:131-141.
73. Munoz-Planillo R., Kuffa P., Martinez-Colon G., Smith B.L., Rajendiran T.M., Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38:1142-1153.
74. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
75. Subramanian N., Natarajan K., Clatworthy M.R., Wang Z., Germain R.N. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 2013, 153:348-361.
76. Misawa T., Takahama M., Kozaki T., et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013, 14:454-460.
77. Barker B.R., Taxman D.J., Ting J.P. Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol 2011, 23:591-597.
78. Dinarello C.A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011, 41:1203-1217.
79. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013, 4:289.
80. Dias-Melicio L.A., Fernandes R.K., Rodrigues D.R., Golim M.A., Soares A.M. Interleukin-18 increases TLR4 and mannose receptor expression and modulates cytokine production in human monocytes. Mediators Inflamm 2015, 2015:236839.
81. Wen H., Gris D., Lei Y., et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011, 12:408-415.
82. Youm Y.H., Adijiang A., Vandanmagsar B., Burk D., Ravussin A., Dixit V.D. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011, 152:4039-4045.
83. Stienstra R., van Diepen J.A., Tack C.J., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011, 108:15324-15329.
84. Esser N., L'Homme L., De Roover A., et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013, 56:2487-2497.
85. Kiraz S., Ertenli I., Arici M., et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 1998, 16:721-724.
86. Miyachi Y., Taniguchi S., Ozaki M., Horio T. Colchicine in the treatment of the cutaneous manifestations of Behcet's disease. Br J Dermatol 1981, 104:67-69.
87. Imazio M., Brucato A., Cemin R., et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011, 155:409-414.
88. Yang L.P. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout. Drugs 2010, 70:1603-1613.
89. Bhattacharyya B., Panda D., Gupta S., Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008, 28:155-183.
90. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008, 10:218-227.
91. Sari I., Yuksel A., Kozaci D., et al. The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever. Inflammation 2012, 35:1191-1197.
92. Ben-Chetrit E., Bergmann S., Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006, 45:274-282.
93. Nidorf M., Thompson P.L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007, 99:805-807.
94. Deftereos S., Giannopoulos G., Kossyvakis C., et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 2012, 60:1790-1796.
95. Yu T.F., Gutman A.B. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961, 55:179-192.
96. Deftereos S., Giannopoulos G., Raisakis K., et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol 2013, 61:1679-1685.
97. Burstein R., Seidman D.S., Zemer D., et al. Chronic colchicine treatment does not impair glucose tolerance in familial Mediterranean fever patients. Eur J Clin Pharmacol 1997, 52:27-30.
98. Wang L., Sawhney M., Zhao Y., Carpio G.R., Fonseca V., Shi L. Association between colchicine and risk of diabetes among the veterans affairs population with gout. Clin Ther 2015, 37:1206-1215.
99. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013, 61:404-410.
100. Zemer D., Livneh A., Danon Y.L., Pras M., Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991, 34:973-977.
101. Levy M., Eliakim M. Long-term colchicine prophylaxis in familial Mediterranean fever. Br Med J 1977, 2:808.